Prelude Capital Management, LLC Relmada Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $7,335 - $11,210	-2,958 Reduced 15.9%	15,642 $46,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $4,218 - $6,726	1,900 Added 11.38%	18,600 $45,000
Q1 2023 May 15, 2023	BUY	$2.24 - $4.76 $37,408 - $79,492	16,700 New	16,700 $37,000
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $2,877 - $6,064	-121 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $1,222 - $5,708	121 New	121 $5,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.